In business for just a decade, Akesobio's stats are mindboggling: Twenty drug development programs, including 12 antibodies in clinical-stage development, six bispecific antibodies (two at clinical stage), four antibodies with IND approvals from the FDA, and 22 clinical trials initiated. CEO Michelle Xia, Ph.D., joins Business of Biotech this week to discuss the company’s supercharged growth. Listen now and subscribe so you never miss an episode.
This is part two of a Q&A with Michael Byrnes, CFO at eFFECTOR Therapeutics, a company currently in the process of de-SPAC-ing a May 2021 announced special purpose acquisition company (SPAC) with Locust Walk Acquisition Corp.
When is it time for an emerging biopharma company to truly emerge, and what goes into its competitive positioning? Biopharma industry veteran Allan Shaw shares insight into developing a differentiation strategy on an increasingly crowded, and evermore complex, playing field.